

PUMA BIOTECHNOLOGY, INC.  
Form DFAN14A  
January 04, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**SCHEDULE 14A**

**(Rule 14a-101)**

**INFORMATION REQUIRED IN CONSENT STATEMENT**

**SCHEDULE 14A INFORMATION**

**Consent Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Consent Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Consent Statement
- Definitive Additional Materials
- Soliciting Material Under Rule 14a-12

**PUMA BIOTECHNOLOGY, INC.**

**(Name of Registrant as Specified in Its Charter)**

**FREDRIC N. ESHELMAN, PHARM.D.**

**JAMES M. DALY**

**SETH A. RUDNICK, M.D.**

**KENNETH B. LEE, JR.**

**(Name of Persons(s) Filing Consent Statement, if Other Than the Registrant)**

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

Fee paid previously with preliminary materials:

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

(1) Amount previously paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

**FREDRIC N. ESHELMAN**

January 4, 2016

Dear Fellow Puma Investors,

I am writing to you, on my own behalf and on behalf of my fellow board slate nominees, to ask for your support in adding four additional members to the current five-member board of Puma Biotechnology Inc. (the Company). The current management and board have presided over share price erosion resulting in the loss of thousands/millions of dollars by individual shareholders, and purportedly up to a billion dollars by institutional firms. None of us should tolerate this any longer. Shareholders deserve better.

In our view board enhancement is needed to address several issues:

Lack of Transparency: The current CEO/Chairman, with apparent board acquiescence, has run the Company with a lack of transparency and refusal to respond to legitimate and legal shareholder inquiries.

Misleading Statements: The Company has repeatedly made misleading statements that were subsequently refuted by actual data. This has seriously eroded share price and resulted in huge destruction of shareholder value.

No Evidence of Launch Preparation: The Company claims to be submitting an NDA in Q1 16 for use in the adjuvant setting for breast cancer. We have heard nothing about regulatory (e.g., pre-NDA meeting with FDA), manufacturing or commercial activities to support an early Q1 17 launch (in the event that the drug is approvable).

Lack of Specific Plans: Ongoing and likely required clinical studies will cost significantly above current cash resources. Analysts' estimates for equity raises to get to cash flow positive would indicate dilution of \$5-10 per share at current prices, with no specific plans for meeting these needs discussed.

Current Board is Unprepared to Deal With Near-term Challenges: Near-term data reveals are mostly complete and the operational and regulatory path forward significantly more complex. The Company will need to develop, and be prepared to execute on, detailed strategies for the commercialization of neratinib. Thus, the task now becomes careful and comprehensive coordination of many activities, and continuous evaluation of strategic options, all of which requires significant time and review by board members.

Please see our updated investor presentation, which is enclosed as an attachment to this letter, in support of our proposals to enlarge the Company's board from five to nine members and elect myself and three other highly qualified director nominees as directors of the Company.

We are disappointed that ISS and Glass Lewis, while fundamentally acknowledging many of our concerns, concluded that change is not necessary at this time. However, Proxy Mosaic has endorsed our proposal and validated our view that [t]he Board's stewardship failures have been directly linked to the Company's recent devaluation and narrowing prospects. Proxy Mosaic's report underscores the fact that there is a very real danger that [neratinib's] commercial potential will not be realized due to the Board's mismanagement. The timing of Dr. Eshelman's campaign could not be better. Further, Proxy Mosaic affirmed that the additional directors would have a strong positive effect on overall oversight and accountability, neither of which appear to be particularly valuable commodities for the current Board.

The Company is at an extremely important point, with regulatory, financing and commercial issues all of critical importance. Our proposal to bring more talent and experience to the board will enhance Puma's ability to successfully navigate to successful outcomes. We are committed to doing the hard work necessary to restore value for shareholders and potentially benefit patients, rather than simply selling our shares and moving on. I am spending several millions of my own money to try to make this right for all of us.

We are asking that you support our consent solicitation to add very experienced and credentialed nominees to the current board. There is no down side to adding four directors who will provide the Company with the tactical know-how and breadth of experience to address the challenges above.

We would very much appreciate your support.

Sincerely,

/s/ Fredric N. Eshelman

Enclosure: Updated Investor Presentation

#### **Additional Information and Certain Disclosures**

Dr. Eshelman is the beneficial owner of 150,000 shares of common stock of the Company, representing approximately .5% of the Company's outstanding shares, based upon the 32,435,748 shares of common stock reported by the Company to be outstanding as of November 2, 2015 in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 9, 2015.

Dr. Fredric N. Eshelman, James M. Daly, Dr. Seth A. Rudnick and Kenneth B. Lee, Jr. (collectively, the "Participants") have filed a definitive consent statement and accompanying form of consent card with the SEC to be used in the connection with the solicitation of consents (the "Consent Solicitation") from the stockholders of Puma to increase the size of the Company's board of directors from five to nine members and elect four new directors. Stockholders of the Company should read the definitive consent statement and other documents related to the Consent Solicitation because they contain important information, including additional information related to the Participants and a description of their director or indirect interests by security holdings. The definitive consent statement and accompanying consent card have been furnished to some or all of the Company's stockholders and are, along with other relevant documents, available at no charge on the internet at [www.okapivote.com/pumabiotechnology](http://www.okapivote.com/pumabiotechnology) or on the SEC's website at <http://www.sec.gov/>. In addition, Okapi Partners LLC, Dr. Eshelman's consent solicitor, will provide copies of the definitive consent statement and accompanying consent card without charge upon request by calling (877) 869-0171 or by emailing [info@okapipartners.com](mailto:info@okapipartners.com).

#### **Investor Inquiries:**

Okapi Partners LLC

Bruce Goldfarb / Pat McHugh / Lydia Mulyk

(212) 297-0720 or (877) 869-0171

info@okapipartners.com

**Media Inquiries:**

Finsbury

Kal Goldberg/ Chuck Nathan / Chris Ryall

(646) 805-2000

kal.goldberg@finsbury.com

charles.nathan@finsbury.com

chris.ryall@finsbury.com

PUMA BIOTECHNOLOGY, INC.  
CONSENT SOLICITATION  
Information for Investors  
January 2016

Certain Disclosures

2

DR. FREDRIC N. ESHELMAN ( DR. ESHELMAN ) DOES NOT ASSUME RESPONSIBILITY FOR INVESTMENT DE  
PURCHASE OR SALE OF ANY SECURITY. UNDER NO CIRCUMSTANCES IS THIS PRESENTATION TO BE USED C  
AN OFFER TO BUY ANY SECURITY. IT IS POSSIBLE THAT THERE WILL BE DEVELOPMENTS IN THE FUTURE  
TIME TO SELL ALL OR A PORTION OF THEIR SHARES IN OPEN MARKET TRANSACTIONS OR OTHERWISE IN  
MARKET OR PRIVATELY NEGOTIATED TRANSACTIONS OR OTHERWISE) OR TRADE IN OPTIONS, PUTS, CALL

SHARES.

DR. ESHELMAN RESERVES THE RIGHT TO CHANGE ANY OF HIS OPINIONS EXPRESSED HEREIN AT ANY TIME. DR. ESHELMAN HAS NO OBLIGATION TO UPDATE THE INFORMATION CONTAINED HEREIN. CERTAIN DATA AND INFORMATION USED HEREIN HAS BEEN OBTAINED FROM SOURCES THAT DR. ESHELMAN BELIEVES TO BE RELIABLE, IS SUBJECT TO CHANGE AND SUCH INFORMATION MAY NOT CONTAIN ALL MATERIAL INFORMATION CONCERNING THE SECURITIES WHICH MAY BE THE SUBJECT OF THIS OFFER. DR. ESHELMAN HAS OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION INDICATED IN THIS ANALYSIS FROM STATEMENTS MADE OR PUBLISHED BY THIRD PARTIES. ANY SUCH STATEMENTS OR INFORMATION ARE NOT THE PROPERTY OF DR. ESHELMAN OR THIRD PARTY FOR THE VIEWS EXPRESSED HEREIN.

DR. ESHELMAN MAY HAVE RELIED UPON CERTAIN QUANTITATIVE AND QUALITATIVE ASSUMPTIONS WHICH ARE NOW BEING ARTICULATED AS PART OF SUCH ANALYSES. THE REALIZATION OF THE ASSUMPTIONS ON WHICH SUCH ANALYSES ARE BASED ARE SUBJECT TO UNCERTAINTIES, VARIABILITIES AND CONTINGENCIES AND MAY CHANGE MATERIALLY IN RESPONSE TO CHANGES IN SUCH ASSUMPTIONS, INCLUDING THE INTERACTION OF SUCH ELEMENTS. FURTHERMORE, THE ASSUMPTIONS ON WHICH SUCH ANALYSES ARE BASED ARE ARBITRARY, MAY BE MADE AS OF THE DATE OF THE ANALYSES, DO NOT NECESSARILY REFLECT HISTORICAL RESULTS THAT MAY BE CONTAINED IN THE ANALYSES, AND DO NOT CONSTITUTE A PRECISE PREDICTION AS TO FUTURE RESULTS. BECAUSE OF THE UNCERTAINTIES AND SUBJECTIVE JUDGMENTS INHERENT IN SELECTING THE ASSUMPTIONS ON WHICH SUCH ANALYSES ARE BASED, FUTURE EVENTS AND CIRCUMSTANCES CANNOT BE PREDICTED, THE ACTUAL RESULTS REALIZED MAY DIFFER MATERIALLY FROM NOTHING INCLUDED IN THESE ANALYSES CONSTITUTES ANY REPRESENTATION OR WARRANTY BY DR. ESHELMAN. NO WARRANTY IS MADE BY DR. ESHELMAN AS TO THE REASONABLENESS, ACCURACY OR SUFFICIENCY OF THE INFORMATION CONTAINED HEREIN TO ANY OTHER FINANCIAL INFORMATION THAT IS CONTAINED IN THE ANALYSES, INCLUDING THE ASSUMPTIONS ON WHICH SUCH ANALYSES ARE BASED. DR. ESHELMAN SHALL NOT BE LIABLE FOR EITHER (I) ANY ERRORS OR OMISSIONS MADE IN DISSEMINATING THIS INFORMATION OR DAMAGES (INCIDENTAL, CONSEQUENTIAL OR OTHERWISE) WHICH MAY ARISE FROM YOUR OR ANY OTHER PERSON'S RELIANCE ON THIS INFORMATION HEREIN.

THE INFORMATION THAT IS CONTAINED HEREIN SHOULD NOT BE CONSTRUED AS FINANCIAL, LEGAL, INVESTMENT OR TAX ADVICE. YOU SHOULD UPON YOUR OWN EXAMINATION AND THAT OF YOUR PROFESSIONAL ADVISORS, INCLUDING LEGAL COUNSEL, ACCOUNTANTS, TAX, REGULATORY, OR ACCOUNTING TREATMENT, SUITABILITY, AND OTHER ASPECTS OF THE ANALYSES. DR. ESHELMAN, JAMES M. DALY, SETH A. RUDNICK AND KENNETH B. LEE, JR. (TOGETHER WITH THE COMPANY) ON NOVEMBER 18, 2015, DR. ESHELMAN, JAMES M. DALY, SETH A. RUDNICK AND KENNETH B. LEE, JR. (TOGETHER WITH THE COMPANY) DEFINITIVE CONSENT STATEMENT AND ACCOMPANYING FORM OF CONSENT CARD WITH THE SECURITIES OFFERING CIRCULAR AND PROXY STATEMENT TO BE USED IN CONNECTION WITH THE SOLICITATION OF CONSENTS (THE "CONSENT SOLICITATION") TO INCREASE THE SIZE OF THE COMPANY'S BOARD OF DIRECTORS FROM FIVE TO NINE. DR. ESHELMAN, JAMES M. DALY, SETH A. RUDNICK AND KENNETH B. LEE, JR. (TOGETHER WITH THE COMPANY) STOCKHOLDERS OF THE COMPANY ARE ADVISED TO READ THE DEFINITIVE CONSENT STATEMENT AND ACCOMPANYING FORM OF CONSENT CARD AND THE PARTICIPANTS BECAUSE THEY CONTAIN IMPORTANT INFORMATION, INCLUDING ADDITIONAL INFORMATION CONCERNING THEIR DIRECT OR INDIRECT INTERESTS BY SECURITY HOLDINGS. THE DEFINITIVE CONSENT STATEMENT AND ACCOMPANYING FORM OF CONSENT CARD IS AVAILABLE TO SOME OR ALL OF THE COMPANY'S STOCKHOLDERS AND ARE, ALONG WITH OTHER RELEVANT DOCUMENTS, AVAILABLE ON THE COMPANY'S WEBSITE AT [WWW.OKAPIVOTE.COM/PUMABIOTECHNOLOGY](http://WWW.OKAPIVOTE.COM/PUMABIOTECHNOLOGY) OR ON THE SEC'S WEBSITE AT [HTTP://WWW.SEC.GOV/](http://WWW.SEC.GOV/). IN ADDITION, DR. ESHELMAN, JAMES M. DALY, SETH A. RUDNICK AND KENNETH B. LEE, JR. (TOGETHER WITH THE COMPANY) CONSENT SOLICITOR, WILL PROVIDE COPIES OF THE DEFINITIVE CONSENT STATEMENT AND ACCOMPANYING FORM OF CONSENT CARD BY CALLING (877) 869-0171 OR BY EMAILING [INFO@OKAPIPARTNERS.COM](mailto:INFO@OKAPIPARTNERS.COM).

Bottom Line: Accountability for Management

3

Management actions have resulted in individual stockholders losing millions of dollars, and institutional losses of up to a \$1 billion.

Stockholders should hold management accountable.

Management Team's Business Execution Talent Less Than Outstanding

there is the long list of issues associated with neratinib in the extended adjuvant setting from the erroneous trial design, to the several global amendments (first altering the ExteNET follow-up from 5 years to 2 years and then reinstating the follow-up back to 5 years), and the misguided attempt to pursue approval in the extended adjuvant setting ahead of the metastatic setting. Moreover, there are the significant delays between times data readouts are announced to be reported and when they

are  
actually  
reported,  
the  
numerous  
half-truths  
hidden  
in  
the  
transcripts  
of  
the  
public  
conference  
calls  
with  
analysts,  
and  
the  
constant  
management allusions  
that PBVI will eventually be sold at a substantial premium as was the  
case with Cougar Biotechnology, a company previously owned and sold for a significant profit  
by  
Alan  
Auerbach,  
the  
CEO  
of  
PBVI.  
Overall,  
these  
events  
are  
representative  
of  
a  
management  
team  
that  
appears  
inexperienced  
and  
driven  
by  
hubris.  
Their  
conduct  
has  
undoubtedly

compromised the interests of the company's shareholders.

-P. Arora, Seamist

Capital, reported in Seeking Alpha.

#### Proxy Mosaic Supports Our Campaign

Leading proxy advisory firm Proxy Mosaic has come out in support of our approach to restoring stockholder value:

4

[T]he Company's focus on three-year relative performance ignores the net effect of recent comments issued by management, which caused the market to substantially raise its expectations for Puma, only to reverse course when the Company's statements

proved to be optimistic. (p. 13)

The true value in Dr. Eshelman's nominees is that they possess the range of skills necessary to oversee any of the strategies that the Company could employ going forward (p. 16)

The Board's stewardship failures have been directly linked to the Company's recent devaluation and narrowing prospects there is a very real danger that its commercial potential will not be realized due to the Board's mismanagement The timing of Dr. Eshelman's campaign could not be better (p. 27)

[T]he additional directors would have a strongly positive effect on overall oversight and accountability, neither of which appear to be particularly valuable commodities for the current Board. (p. 27)

We recommend shareholders return the WHITE consent card. (p. 28)

Reaction to ISS  
and Glass Lewis

The recent recommendations by ISS and Glass Lewis also  
validated many of our concerns:

5

[T]he dissident's assertion that Puma's board composition is still not optimal  
may hold some truth. (ISS, page 3)

[I]nvestors  
may be appropriately concerned  
about the company's recent  
trajectory. (ISS, page 13)

Share price returns over the past year has been significantly worse than that of  
its peers the recent significant decline in the Company's share price is hardly  
ideal. (Glass Lewis, page 9-10)

[W]e agree with the Dissident, at least to some extent, that the Company could  
do  
a  
better  
job  
of  
setting  
more  
realistic  
expectations  
for  
its  
clinical  
trials.  
(Glass  
Lewis, page 10)

However, we disagree with the view that change is not  
necessarily  
warranted  
at  
this  
time"  
and  
is  
not  
prudent  
at  
this  
stage  
at this critical juncture, Puma needs an infusion of  
expertise.

Founder of Eshelman

Ventures, LLC, an investment company primarily  
focused on healthcare companies.

Non-Executive Chairman of The Medicines Company, a global  
biopharmaceutical company focused on saving lives, alleviating suffering  
and contributing to the economics of healthcare by focusing on the  
leading acute and intensive care hospitals worldwide.

Founder and former CEO and Executive Chairman of Pharmaceutical Product Development, Inc. ( PPDI ), a global contract pharmaceutical research organization.

Founding Chairman of Furiex

Pharmaceuticals, Inc. ( Furiex ), a company that licensed and rapidly developed new medicines.

Former director and Senior Vice President, Development of Glaxo, Inc., predecessor to GlaxoSmithKline plc.

Education: Pharm.D., University of Cincinnati; B.S., UNC-Chapel Hill.

Fredric N. Eshelman, Pharm.D.

6

PPDI: Total Shareholder Return

Furiex: Total Shareholder Return

Background Of Investment

7

Between May 18, 2015 and June 4, 2015, I purchased a total of 150,000 shares of Puma's common stock.

Between October 22, 2015 and November 3, 2015, I

acquired options to purchase 150,000 shares of Puma s common stock.

Currently, I am the beneficial owner of 150,000 shares, representing approximately .5% of Puma s common stock, after the options expired worthless on December 18, 2015.

Meanwhile, over the last two years, current directors and officers have collectively engaged in net aggregate sales of stock valued at a total of approximately \$18,761,916.57.

1. Source: Transactions listed in Participant Transaction Chart on page 44 of the Company s Definitive Consent Revocation Statement. filed on December 10, 2015. Calculations based on closing price for the date of sale listed.

1

#### Company Overview

Puma Biotechnology, Inc. (NYSE: PBYI) ( Puma or the Company ), a Delaware corporation and development stage biopharmaceutical company, focuses on the acquisition, development and commercialization of products for the treatment of various forms of cancer.

8

Name

% Outstanding

Adage Capital Management LP

17.5%

Fidelity Management &  
Research Co.

14.9%

Alan H. Auerbach

12.5%\*

The Vanguard Group, Inc.

5.5%

Capital Research &  
Management Co. (Global  
Investors)

5.4%

T. Rowe Price Associates, Inc.

5.3%

Grantham, Mayo, Van Otterloo  
& Co. LLC

5.2%

Orbimed

Advisors LLC

3.7%

Franklin Advisers, Inc.

3.0%

Frank Zavrl

2.8%

Alan H. Auerbach

CEO

and President

Richard Bryce

SVP,

Clinical Research and  
Development

Charles R. Eyer

SVP,

Finance and Administration  
and Treasurer

Alan H. Auerbach

Chairman

Jay M. Moyes

Adrian M.

Senderowicz

Troy E. Wilson

Frank E. Zavrl

Headquarters: Los Angeles, CA

Full-time  
Employees  
(12/31/14):  
120

Market Cap (12/22/15): \$2.384 billion

Closing price (12/22/15): \$73.72 per share

\* Excludes 2,116,250 shares exercisable pursuant to anti-dilutive warrant and options to purchase 399,999 shares exercisable within 60 days of April 17, 2015.

Sources: Capital IQ; SEC Filings; Bloomberg; NASDAQ. Amounts as of September 30, 2015 unless otherwise indicated. Calculation of percentage outstanding assumes 32,435,748 shares outstanding as of November 2, 2015, as reported in Form 10-Q filed on November 9, 2015.

Single Drug Candidate  
Neratinib/PB272  
(oral): treatment  
of breast cancer patients and  
exploratory studies in other  
tumors.

Puma presented three-year data from the ExteNET trial of neratinib on December 11, 2015 at the San Antonio Breast Cancer Symposium ( SABCS ).

The two-year data from the ExteNET trial will form the basis of the Company's new drug application ( NDA ) which, according to management, will be filed with the FDA in Q1 2016, according to management. NDA filings are an onerous and complicated process that require significant expertise and experience.

Previous data releases from the ExteNET trial have been the main driver of Puma's stock value, and the latest data release was no exception. This data will be analyzed in more detail to follow.

Company Overview

9

Source: SEC filings

Source: Puma website.

### Why Am I Soliciting Consents?

10

Board and management practices are reducing stockholder value.

Stock price underperformance relative to the biotechnology industry and the Company's closest peers over the most recent six-month and one-year periods. Stockholders have been whipsawed in both directions by management; we have seen significant stock volatility over

the last six to nine months.

History of mismanaging market expectations, including making problematic statements and not meeting announced targets or milestones relating to clinical trials.

Stockholder unfriendly executive compensation practices.

Board  
and  
management  
unresponsive  
and  
not  
transparent

-  
my  
requests  
for  
Company  
documents, including board minutes, through 220 demands under Delaware Corporate Law, were denied after repeated requests. I had to file suit in Delaware to obtain requested stockholder information that is readily available to companies and that I am entitled to as a shareholder.

Nominees would add unique expertise and bring a more stockholder-friendly perspective.

Highly  
qualified  
and  
experienced  
slate  
of  
nominees  
will  
add  
value  
to  
the  
board  
without  
replacing current directors.

Improved oversight of management in executing Puma's value proposition and in navigating assets through the regulatory process.

Initiatives to improve transparency for Puma's investors.

Major near-term clinical data events are over. Now it is a story of regulatory and commercial expertise and experience, which our slate will provide.

Consent Solicitation  
Overview  
11

Consent Solicitation Goals

Increase the size of Puma's board from five to nine directors.

Elect four highly qualified and experienced directors.

No incumbent directors will be replaced.

The Nominees will each add unique expertise and experience to ensure a successful strategy for navigating the development and regulatory process, and ultimately, a strategy for bringing valuable drugs to market.

12

### Consent Solicitation Proposals

#### Proposal 1: Repeal Amendments to the Bylaws

o

Adoption of Proposal 1 will ensure that the current board cannot (i) prevent or impair the stockholders' ability to add the Nominees to the Board or (ii) limit the Nominees' ability to take actions in the best interests of the Company and its

stockholders, if elected.

Proposal 2: Removal of Directors

o

Adoption of Proposal 2 will remove any additional directors appointed after September 9, 2015 and prior to the effectiveness of Proposal 2, but will not remove any current directors.

Proposal 3: Increase the Size of the Board

o

Adoption of Proposal 3 will increase the size of Puma's board from five to nine directors.

Proposal 4: Election of the Nominees

o

Adoption of Proposal 4 will elect the Nominees to serve as directors of the Company.

o

Stockholders may consent to the election of all or some of the Nominees.

13

Dramatic Stock Price Underperformance

Puma shares have significantly underperformed the S&P 500 and NYSE

Arca

Biotechnology Index.

14

Source: Capital IQ

While the Company has performed generally in line with peers since its IPO in 2012

and outperformed last year due to management description of forthcoming trial results and heightened expectations, since disappointing data was released in June 2015 at the at the American Society of Clinical Oncology ( ASCO ) annual meeting, the Company has underperformed and we believe that value will continue to be destroyed if there is no change in the status quo.

Preliminary Consent

Solicitation Filed

Dr. Eshelman Initial

Investment

Initial 220

Demand

Dramatic Stock Price Underperformance

Puma has also significantly underperformed its closest peer companies.

15

Source: Capital IQ

Sharp fall in

Clovis stock due

to prematurely

announcing drug  
responses which,  
subsequently,  
were not  
confirmed.  
Preliminary  
Consent  
Statement  
Filed  
Dr. Eshelman  
Initial  
Investment

16

History of Problematic Statements:

Background

ExteNET Trial Description

Started by Pfizer Inc. in April 2009.

Enrolled 2,840 patients in 41 countries.

Double-blind, placebo-controlled, Phase III trial of neratinib vs. placebo after adjuvant treatment with trastuzumab ( Herceptin ) in women with early stage HER2+ breast cancer.

After one year of adjuvant treatment with Herceptin, patients were randomized 1:1 to receive extended adjuvant therapy with neratinib or placebo for one year.

Patients were then followed for recurrent disease, ductal carcinoma in situ or death for a period of two years after randomization into ExteNET, or three years since the initial start of Herceptin.

Primary  
Trial  
in  
Support  
of  
Q1 16  
NDA

History of Problematic Statements:

Optimistic Statements by Puma

17

The results of the trial demonstrated that treatment with neratinib resulted in a

33% improvement in disease free survival versus placebo.

Puma Press Release,  
July 22, 2014

We saw a 33% improvement in invasive disease-free survival.

-  
Puma Conference call,  
May 7, 2015

Most importantly, a number of those subgroups are extremely differentiating from the other HER2 agents that are commercially available.

So, I think there is certainly the opportunity for the drug to be used in all patients directly after treatment in year one with Herceptin.

Puma Conference Call, July 22, 2014

Analysts  
high  
expectations  
followed:

Beginning on July 22, 2014, and continuing until as late as May 7, 2015, Puma claimed that the ExteNET data would show that neratinib significantly improves results in breast cancer patients over a placebo.

We spoke to Puma about the upcoming abstracts. In addition to what is already known, the abstract from the ph3 ExteNET trial will include the actual 2yr DFS values, and key subset analyses that will show neratinib forms well in populations typically challenging for Perjeta and Kadcyła.

-  
UBS, May 4, 2015

We see upside potential at ASCO, where we think ExteNET data will show well.

-  
UBS, May 5 2015

Given prior comments from PBYI, investors had expectation of at least a

3% absolute benefit, and perhaps a benefit as high as 4-5%.

-

Cowen and Company, May 13, 2015

We continue to expect the

ExteNET

data in Chicago to

show the 3+% difference

between the two arms We

see a low probability of any

negative data surprises

-

RBC Capital Markets, May

11 2015

History of Problematic Statements:  
Impact On Puma's Stock Price

July 22, 2014 closing price: \$59.03. Following market close the Company issued a press release and held a conference call announcing two-year results from the ExteNET trial.

July 23, 2014 closing price: \$233.43.

Stock reached its historical high of \$270.83 per share on September 12, 2014.

18

Puma Biotechnology Inc. soared after the company yesterday reported positive trial results for its breast cancer drug Puma shares almost quadrupled

-Bloomberg, July 23, 2014

Source: Capital IQ

Jul. 22 Release of

Positive ExteNET

Results

Jul. 23 closing

price-

\$233.43

Sept. 12

All-time

High

June 1 ASCO

Presentation

History of Problematic Statements:

Clinical Trial Data Inconsistent With Expectations

19

[T]he absolute magnitude of difference in DFS was trivial. Neratinib's use is likely to be limited to a small subset

Cowen and Company, May 21, 2015

Between May 13, 2015 and June 1, 2015, Puma released additional ExteNET data, which

was  
presented  
at  
the  
ASCO  
annual  
meeting.

The  
newly  
released  
ExteNET  
data  
did  
not  
meet analyst s high expectations.

[T]he point estimate at the 2yr landmark is below the 3pp delta set by investors One can debate the expectation management We recognize anger about expectations coming in.

Most investors and oncologists had approximated the minimum delta between the two arms to be about 3% in order to achieve meaningful clinical significance. On its face, the 2.3% IDFS difference falls below expectations it is not surprising why the stock is down 25%...

RBC Capital Markets, May 14, 2015

UBS, May 13, 2015

20  
While  
the  
Company  
continued  
to  
tout

the  
success  
of  
the  
ExteNET  
trial  
at  
the  
June  
2015 ASCO meeting, significant portions of the analyst, investor, and medical  
communities saw the data and clearly disagreed. Puma's stock price  
plummeted.

History of Problematic Statements:

Clinical Trial Data Inconsistent With Expectations

We believe that the market reacted primarily to management's failure to provide a clear  
explanation

of  
what  
investors  
could  
expect  
from  
the  
ExteNET  
data.

With the release of the three-year data, the Company had an opportunity to learn from its past  
mistakes. It could have pursued a more transparent and realistic approach to managing  
expectations

about  
the  
data.

Instead,  
the  
current  
management  
chose  
to  
confuse  
the  
situation.

ASCO  
Presentation

[W]e view the sell off as  
more of a reaction to  
falling  
short of misguided  
expectations rather than a  
fatal flaw in neratinib's clinical  
profile.

The absolute

treatment benefit over  
placebo (2.3%) was materially  
below where management  
had implied when topline  
data were first  
released in  
July 2014.  
-J.P. Morgan, August 27, 2015

All of These Statements Cannot Be True

21

Q:

And you noted that the  
FDA is not going to ask for  
any more data from  
ExteNET.

But you're now  
essentially a year since you  
actually hit the two-year.

So  
a year from now you're  
going to be the two-year, so  
you're going to be

A: [A]s we mentioned on  
the call when we did for  
announcing the ExteNET  
data,  
the curves are  
continuing to separate.

So  
that obviously would  
strengthen the data set.

-12/2/2014 Conference Call

Q: And then on to San Antonio, you mentioned the three-year analysis. Do you plan to show just the three-year curves or show data to go further out than 3 years?

A:  
I  
would  
ideally  
like  
to  
be  
able  
to  
show  
Kaplan-Meier  
curve  
that  
don't  
just  
truncate  
at  
36  
months.

How  
much  
more,  
I  
don't  
know  
the  
answer  
to you  
yet  
because  
the

data  
is  
still  
blinded.  
We  
have  
not  
unblinded  
it  
yet,  
so  
I  
don't  
know  
the  
answer  
to  
that  
yet.  
Clearly,  
the  
key  
is  
going  
to be  
what  
the  
number  
of  
patient  
at  
risk  
is.  
If  
it's  
just  
that  
the  
cut  
we  
took,  
we  
didn't  
get  
a  
lot  
of  
patients  
out  
further

than  
if  
you're  
down  
to  
50  
patients  
or something toward the 40-, 42-month period that that would be obviously something of concern. I don't think that's going to  
we  
should  
be  
able  
to  
show  
somewhere  
in  
between  
36  
months  
and  
48  
months.

I  
just  
can't  
give  
you  
any  
exact  
numbers  
right  
now.

-11/30/2015 Conference Call

Q:

Alan, in terms of the 2-year disease-free survival endpoint, if you don't need further data, why was the protocol restored and the mandate to improve 5-year results?...

A:

[W]hen we were first giving guidance in what we expected the trial results to show. What we said that well, we expect the curves to be separating, but we don't think they'd be statistically significant by two years.

So they were meant because we anticipated that the two-year would show a trend, but the five-year would actually be what would be statistically significant. Obviously, we are pleased that the curve

separated enough to be positive at the two-year.

But it was originally restored because we thought the curves would be trending by two years, but not near positive.

-

6/2/15 Conference call

Q:

[C]an you give us a sense as to whether the separation is widening over time or how would you describe the curve separation?

A:

If we look at curves going out beyond [two years] it looks like the curves are continuing to separate...

[I]f you

look at curves in the Herceptin adjuvant trials, so the HERA study, the BCIRG

study, et cetera, the absolute difference

in disease-free survival increases as you go out year-over-year...

So, for instance, in the BCIRG

trial, the DFS

difference was

6% at two years, then 7% at three years, then 8% at four years, et cetera, et cetera.

We're seeing the same

preliminary trend in the ExteNET

trial where the curves

appear to be continuing to separate as you go out year-

over-year, and the absolute DFS

difference is increasing

year-over-year as well.

-

7/22/201414 Conference Call

Mr.

Auerbach

made

numerous

statements

before

December

2015

about

the

ExteNET

data,

including

claims

that

the  
DFS  
curves  
were  
separating  
beyond  
the  
two-year  
data.

Yet,  
less  
than  
two  
weeks  
before  
the  
three  
year  
data  
was  
presented,  
Auerbach  
claimed  
that  
he  
could

not tell investors what data would be presented at SABCS, as the data was still blinded.

When did Puma see the DFS

data for years 3-5? If the data was blinded, what was the basis for Auerbach's  
previous

statements? If the statements were based on the data, why did Puma claim that it was blinded and avoid being  
transparent with investors?

December 11, 2015: Another Missed Opportunity

22

The actual two and three-year results differed materially from guidance given by management prior to release. While the stock price has rebounded, share prices are still down more than 60% over the last five quarters, erasing billions of dollars in stockholder value. 2015 SABCS

has done

nothing to improve the Puma's position or solve any of its problems.

When the three-year ExteNET data was finally released, the curves did not separate.

DFS results in all indications decreased from Year 2 to Year 3, other than HER2+/HR+ results, which were not meaningful.

\*Subsequently changed to 2.5% based on additional data.

12/11/2015 SABCS:

Stock drops as much as 22%, closing down almost

6%

Year 2

Year 3

Indication

Absolute

Difference in

DFS

Absolute

Difference in

DFS

Primary

2.3%\*

2.1%

Centrally Read HER2+

4.1%

2.2%

HER2+/HR+

4.2%

4.3%

Centrally Read HER2+ and HR+

8.6%

6.4%

The market has spoken loudly about its lack of confidence in current management.

History of Problematic Statements:  
Regulatory Plan and Cancer Indication  
23

Source: Capital IQ

Yes, we are still planning to file the NDA for the ExteNET Study in the first half of 2015.

-

Alan Auerbach, Conference Call,  
November 13, 2014

Since the Company's initial NDA filing will now be for the extended  
adjuvant HER2-positive early stage breast cancer indication  
Puma intends to delay its proposed timeline for filing the NDA until  
the first quarter of 2016.

-

Puma Press Release,  
December 2, 2014  
ExteNET

is  
not  
an  
aberration

-

management  
has  
a  
history  
of  
mismanaging  
market  
expectations.

For  
example,  
Puma  
stated  
on  
several  
occasions,  
including  
as  
late  
as  
November  
13,  
2014,  
that  
it  
would  
file  
an  
NDA  
for neratinib during the first quarter of 2015.

Less  
than  
three  
weeks

later,  
on  
December  
2,  
2014,  
Puma  
pushed  
the  
projected  
date  
of  
its  
NDA  
filing  
to  
the  
first  
quarter of 2016.  
12%  
Decline

Puma may claim that the delay was due to the FDA's requirement that the Company file carcinogenicity data, and that it had no control.

We believe that the company should have known that this data would be required because filing for a long-term indication always requires this data.

We believe that Puma mismanaged the regulatory process.

History of Problematic Statements:

Other Trials

24

The Company held a conference call on December 23, 2013 to discuss HER2 mutation trials.

We have tried to locate the transcript but have been unable to do so.

As far as we can tell, the transcript seems to be missing and unavailable.

However, according to reports written by at least two analysts about the call:

With respect to the refractory NSCLC trial, Mr. Auerbach stated that response rates in both arms of the trial were in the 40-49% range.

Data released on September 9, 2014 was not consistent with the earlier statement (N=27).

NERAT

NERAT + TORISEL

Partial Response

0

3 (21%)

Stable Disease

7 (54%)

11 (79%)

Clinical benefit

4 (31%)

9 (64%)

History of Problematic Statements:  
Public Disclosures & Drug Development Process  
25  
Clinical Trials

Equivocating on the extent of data to be presented in December 2015 on ExteNET  
and other trials.

Public Filings

In its S-1/A filed on October 17, 2012, the Company outlined its business strategy:

S-1/A Strategy

Current

Status

An Investigational

New Drug Application

( IND )

would

be filed for the IV form of neratinib in 2013.

The Company has not filed an IND for the IV form of neratinib.

The Company would in-license additional compounds.

The Company has not licensed any additional compounds.

ExteNET

trial would be wound down.

Important

data

from

the

ExteNET

trial

was

only

released in December 2015.

Compound PB357

would be evaluated for further development in 2013.

2013 10-K: We are evaluating PB357

and considering

options relative to its development in 2013.

2014 10-K: We are evaluating PB357

and considering

options relative to its development in 2014.

2015 10-K: We are evaluating PB357

and considering

options relative to its development in 2015.

Failure to Address Key Issues: Tolerability Profile  
Crucial Issue

If  
two  
or  
three

patients  
out  
of  
every  
ten  
are  
affected,  
neratinib  
has  
a  
major  
problem.

With approximately 2% DFS, MDs must treat 50 patients to benefit one, while treating just three patients will impair the quality of life in one.

Failure  
to  
significantly  
reduce  
grade  
3  
diarrhea  
or  
perceived  
diminished  
DFS  
benefit  
over time  
will result in a major reduction in addressable population.

Severe  
diarrhea  
was  
evident  
with  
neratinib  
even  
in  
the  
early  
PFE  
data.

Why didn't Puma incorporate protocol amendments much earlier for grade 3 diarrhea prophylaxis?  
Why haven't trials looking at these issues been more rigorous?

On  
December  
11,

2015,  
Puma  
released  
interim  
results  
from  
an  
open  
label  
trial  
in  
BC  
adjuvant  
patients with varying treatment duration. Of the 72 patients in the trial, only 50 were  
evaluatable  
(approximately 30%  
were  
unevaluatable).  
The  
loperamide  
dosage  
was  
changed  
mid  
study.

The overall results of 16% grade 3 diarrhea were then compared to a table showing a variety of  
drugs/combinations for more serious indications, not adjuvant, and then attempting to draw  
comparative conclusions.

This is voodoo science and will not hold up in regulatory or commercial situations.

o  
Stockholders  
were  
also  
unimpressed

Puma's  
stock  
price  
did  
not  
even  
recover  
to  
its level  
from the previous week .  
Inconsistent Results

In the NSABP FB-7 trial, three of the four arms that utilized the prophylaxis had significantly higher

rates (30%, 35% and 23%). The patients in the cohort of the SUMMIT basket trial presented at SABCS also had a higher rate (35%).

26

Can stockholders rely on current management to handle this issue from either a regulatory or commercial standpoint?

M&A  
Speculation  
27  
There  
has  
been  
speculation

regarding  
M&A  
for  
quite  
some  
time.

Analysts  
have  
also  
commented:  
Cowen 5/5/15:

..[F]uture  
stock performance appears increasingly dependent on M&A, an outcome we  
have little visibility on.

Puma management has acknowledged that a sale of the company may be the optimal  
way  
to  
maximize  
shareholder  
value  
and  
allow  
neratinib  
to  
realize  
its  
full  
potential. In  
our  
view, Puma is likely to generate significant acquisition interest...

[O]ur  
optimism  
for  
an  
M&A  
exit  
is  
somewhat  
tempered  
by  
the  
fact  
that  
[Puma]  
has  
been  
investigating a potential sale for several months...

UBS 5/4/15:

We reiterate our Buy rating and see Puma as a prime acquisition candidate.  
Interestingly,

right  
around  
the  
early  
May  
timeframe,  
the  
SVP  
of  
BD  
left  
the  
Company.

UBS 5/20/15:

Will Puma be acquired?

We have felt that there isn't a rush to acquire until the calendar flips to 2016 so that it's  
dilutive

only  
for  
one  
year  
and  
carc/filing  
is  
de-risked.

That  
said,  
one  
reason  
to  
move  
sooner  
rather  
than  
later  
is  
to  
execute  
on  
the  
long-duration  
trials  
to  
max  
out  
the  
tail  
potential.

CVRs

may be acceptable to reflect upside sales optionality.

However, a company must always be run under the assumption that there may never be an M&A offer that fully reflects value and is in the best interest of shareholders.

Stockholder Discontent

28

Auerbach and Eyler received nearly \$22.3 million in salary and incentive-based annual compensation in 2014 alone, all materially enhanced as a result of deceiving the investing public...

-Stockholder Consolidated Complaint, October 16, 2015

A stockholder class action complaint was filed on June 3, 2015 in the U.S. District Court for the Central District of California against Puma, Alan Auerbach and Charles Eyler.

In the complaint, the stockholder plaintiffs alleged violations of federal securities laws, including claims under Sections 10(b) and 20(a) of the Exchange Act, stemming from Defendants' allegedly problematic statements and failure to disclose material adverse facts regarding the results of the ExteNET trial and the efficacy of neratinib.

The plaintiffs allege that the defendants, including Auerbach and Eyler, engaged in a scheme to deceive investors and the market and a course of conduct that artificially inflated the price of Puma stock and operated as a fraud or deceit on Class Period purchasers of Puma stock by misrepresenting and omitting material information about neratinib.

The outcome of the stockholder litigation is currently pending. The Company's problematic statements have already led some stockholders to take legal action.

Stockholder Unfriendly Executive  
Compensation  
29

Compensation is excessive and not aligned  
with stockholder interests.

No formula based incentive plan (noted by ISS and Glass Lewis).

Equity plan is dilutive.  
See Appendix A for more details

Failure to Respond to 220 Demand

Puma's current board and management are not sufficiently committed to transparent disclosure or responsive to legitimate stockholder concerns.

In July 2015, I exercised my right as a stockholder under DGCL Section 220 to request copies of the Company's board minutes.

o

My request was narrowly tailored for the purpose of enabling me to analyze and value my ownership stake.

o

The Company engaged in a pattern of delays and requested additional time to respond.

o

Eventually, the Company claimed that it is under no obligation to comply based on its belief that I did not have a legal basis for the request.

o

I strongly disagree with their position and I provided a valid purpose for the requested materials.

On October 29, 2015 and concurrent with the launch of this consent solicitation, I delivered a second request to inspect the Company's stockholder lists pursuant to DGCL Section 220.

o

Initially, the Company provided limited information purportedly in satisfaction of the request, and only committed to provide all of the legally required documents after I filed suit in the Delaware Courts.

30

The Company's response reflect the board's lack of transparency and an unwillingness to respond to the legitimate concerns of stockholders.

Value Proposition

Value Proposition And Caveats

32

Potential Value

Depending on how various indications for use are valued commercially, and the assigned probability of technical and regulatory success, Puma shares may yet offer investors a value proposition.

However, we do not see any path back to previous prices (>\$250) and unlikely that much over \$100 per share is attainable.

This view is shared in recent analysts reports with the exception of one who appears to be close with management.

M&A rumors have swirled around the Company as far back as 2013.

As recently as 14 December 2015, RBC said that We view an acquisition by a big biopharma as the most likely outcome.

In the same report, they cut their price target from \$285 to \$103.

In August 2015 JPM said, .we believe there are too many cards left

to  
be  
unturned  
for  
a  
suitor  
to  
pull  
the  
trigger  
right  
now.

While  
some  
of  
the  
cards  
were  
revealed  
at  
the

SABCS, generally investors were disappointed and the stock fell again.

Since management has a history of making misleading and problematic statements not backed up by actual data, any company having a look at Puma would undoubtedly conduct rigorous and lengthy due diligence.

Even  
then  
it  
is  
improbable  
that  
any  
binding  
offer  
would  
be  
made  
ahead  
of  
FDA  
and  
EMA  
submissions,

as  
well  
as  
waiting to be sure that regulatory authorities would actually file the Applications.

It  
is  
just  
too  
tight  
to  
rely  
on  
M&A  
as  
a  
strategy  
with  
a  
Q1  
16  
NDA  
submission  
and  
a  
potential launch early Q1

17.

Therefore, massive regulatory, manufacturing and commercial efforts must be underway now to meet the proposed launch date.

Extended Adjuvant Claim

Puma says it will submit a US NDA Q1

16 for use of neratinib

in the extended

adjuvant setting based on the results of the ExteNET

Trial.

They indicate that FDA

will evaluate the NDA based on two-year DFS as the protocol primary endpoint.

Recently, however, management did waffle about not having heard from FDA about the possibility of needing five-year data.

We have concerns about the viability of this plan:

Trial Design:

There are many issues associated with the trial:

Several protocol changes

High dropout/censoring rates,

40% occurrence of Grade 3 diarrhea,

Potential unblinding

of the trial due to the huge incidence of severe diarrhea in the treatment arm.

33

Small Treatment Effect:

As shown previously, the DFS

at 3 years was down vs. 2-year rates in every

subgroup except HR+ (no central read of HER2), and even there the rate change was immaterial (4.2% to 4.3%).

No effect was seen in the HR-group.

Many physicians have indicated that the small overall treatment effect at the expense of a high rate of severe diarrhea would not make them inclined to use the drug routinely.

Extended Adjuvant Claim

34

Much of the residual value still resides in the adjuvant claim, so a rocky road here would change the valuation outlook substantially.

Approvability Questions:

Management

has

ballyhooed  
the  
DFS  
effect  
in  
the  
HR+  
subgroup,  
but  
this  
was  
not  
predefined

as the primary endpoint, and thus is unlikely to result in an approval without additional work.

Even if one were optimistic and accepted the likelihood of getting the HR+ claim, this cuts into the overall population in the adjuvant setting, without even considering competitive threats like Perjeta and ONT 380.

JPM  
was also skeptical about the approval process:

[A]pproval  
is not a shoe-in by any stretch. We expect the risk-benefit profile will be highly scrutinized by the Agency, especially given the well known GI toxicities. JP Morgan, Dec. 2015

We don't expect the review process to be smooth sailing for neratinib, as we anticipate that it could come under heavy scrutiny JP Morgan, Aug. 2015

Lack of Regulatory Preparation:

We  
have  
heard  
nothing  
about  
a  
pre-NDA  
meeting  
with  
FDA  
with  
respect  
to

the  
application.

A  
request must be submitted 60 days prior to the meeting, and briefing data must go in 30 days  
prior  
to  
the  
meeting.

So  
if  
Puma  
wants  
to  
submit  
an  
NDA  
in  
Q1  
16,  
this  
request  
should  
have

already been made in order to provide adequate time to react/modify following the meeting  
and prior to submission.

Other Claims for Use

The Company's original strategy was to make metastatic breast cancer the first submitted application.

While

some information has been

released here, there is no body

of data that we are aware of that would imply a submission for

this indication in the near future.

There have also been some off-the-cuff remarks about the possibility of submitting for a neoadjuvant claim.

However, recently released data in this setting was disappointing, and RBC removed neoadjuvant from their valuation model.

Two years ago the Company said, Puma's company goal is clearly to move neratinib into Phase III in the neoadjuvant setting. (12/4/13)

We do not know where this stands.

Likewise, other areas such as mutated HER2, CNS metastasis and other solid tumors are supported by very limited data and do not appear to be near-term possibilities.

35

Impact of the SABCS Data Release

Puma has been spinning the new data as positive due to the increase in DFS for the HER2+, HR+ subset. We have several concerns about this proposed strategy:

Regulatory:

The  
FDA

may  
not  
allow  
the  
Company  
to  
use  
ExteNET  
subgroup  
analysis  
as the basis for an NDA approval because it was not the pre-selected primary  
endpoint.

Market Share:

Even in the best case scenario, the HER2+, HR+ centrally confirmed  
subset is not large enough to support the type of sales that would be necessary to  
justify the Company's current market cap. If the approval is limited to a series of  
small subsets, it will be very difficult for a small company like Puma to execute a  
commercialization plan.

Sales:

Building a sales force a serious challenge that could create significant  
operating losses in the future.

Partnerships:

Any attempt to commercialize via partnership will likely harm the  
Company economically.

M&A:

It seems unlikely that there will be any acquirers for Puma until the regulatory  
situation has been clarified.

36

Puma's options are becoming more limited and more expensive.  
High risk from the standpoint of probability of technical and regulatory  
success, thereby requiring a thoughtful, objective, reality based  
strategy going forward.

#### Overall Position

Here is what JP Morgan had to say in two recent reports (August and December 2015):

o

[T]he spotlight will now shift to progress with regulators.

o

[N]eratinib's commercial prowess remains a major question mark, if it even gets that far.

o Even if approved, reversing sentiment on neratinib could be a Herculean task.

o Therefore we believe that Puma faces a daunting task to shift the negative perception of its lead product.

We agree with all of these statements.

As pointed out before, there is no evidence of a comprehensive plan to get the drug approved and positioned correctly, have all of the manufacturing issues dealt with and launch stocks available, and do the upfront commercial work necessary to be ready to launch the drug.

Relying on M&A at an acceptable valuation in the immediate future is a huge gamble, and if it does not happen shareholders will once again be left holding the bag.

Now, more than ever, the Company needs an infusion of highly experienced board members in

all  
aspects  
of  
technical/regulatory,  
commercial,  
M&A  
and  
finance.

37

Shareholders deserve a better shot at restoration and enhancement of value.

Our Plan to Improve Transparency

The Nominees will work with management to improve transparency and manage street and investor expectations, specifically by providing greater clarity with respect to the following issues:

Confirm Q1 16 NDA for extended adjuvant and possible neoadjuvant indication.

Address carcinogenicity data if problematic.

Events triggering payments of \$187 million milestones due to PFE; cash flow to support R&D going forward, and potential needs for additional financing.

Refine  
and  
disclose  
regulatory  
and  
other  
plans  
in  
place  
in  
response  
to  
ExteNET  
results,  
other  
claims,  
etc.

Correct any previous problematic statements and improve expectations provided by management going forward.

Make management (as appropriate) other than CEO available on conference calls, meetings, etc.

Give complete outline of ongoing/planned studies, with firm reporting times.

Give complete report of all trial results (or topline at least) ready but heretofore unreleased (Pfizer and Puma).

Show how all of the above line up with commercial expectations and valuations for various indications.

Update on Perjeta and other competitive threats.

PR with oncology community in order to promote better understanding of drug effects and prevention/management of side effects.

Disclose firm, detailed business plan and value enhancing strategy.

38

In this uncertain environment, transparency is especially important for investors. Unfortunately, Puma has lacked transparency in the past.

We

seek to increase transparency and achieve full value for stockholders.

**Business Initiatives Nominees Plan to Pursue**

The Nominees have outlined a set of business initiatives that address the following areas that they have identified as critical to their oversight function and a value-maximizing strategy:

39

While it is difficult to know precisely what actions should be taken without full data access, it is quite clear that an overall comprehensive plan must be adopted and executed expeditiously.

Unfortunately, the current board has not been fully transparent, and has not engaged in public discussion of important issues including: integrating/launching commercial planning, manufacturing/finishing launch stocks of drug, looking at cash flow to support this activity.

The current board has given no indication that such comprehensive planning/implementation has been done.

The Nominees are committed to helping Puma develop a comprehensive plan.

1.  
Regulatory, Clinical and R&D Plan
2.  
Commercial/Competitive Situation, Label Indications and Valuations, Marketing and Sales Plan Preparatory Activities
3.  
Manufacturing Considerations
4.  
Finance and Business Development
5.  
Investor Relations and Corporate Communications
6.  
Governance, Management Evaluation, Board Self-Study

Minority Slate of Highly  
Qualified Nominees  
40

#### Highly Qualified Slate of Nominees

The Nominees have the experience and expertise to help guide Puma down the complicated path to a successful launch of neratinib:

41

Dr. Eshelman invested in Puma, undertook this consent solicitation, and assembled an outstanding nominee slate because he believes in the opportunity neratinib presents and is committed to bringing this valuable drug

to the market, with the ultimate goal of improving cancer care for patients.

Highly qualified with excellent, relevant track records and significant experience, comparing favorably with current directors.

Proven commitment to enhancing stockholder value and to patient care.

Addition of four new directors brings breadth and depth to the current board of directors.

No incumbent directors will be removed.

Each of the Nominees is independent of Dr. Eshelman and will fulfill their fiduciary duties to act in the best interest of all Company stockholders.

Optimal Board Size: Nine is Fine  
Of 31 peer companies identified by either ISS, Capital IQ, or  
Bloomberg:

Seven peers have boards with nine directors.

Notably, CEO Alan Auerbach sits on the board of Radius

Health

Inc., which has nine members.

Radius Health's

market cap and product pipeline are similar to Puma's.

13 peer boards have nine or more members.

NONE

of Puma's peers has a board with fewer than six members.

42

ISS: A board of between nine and 12 members is considered ideal.

Glass Lewis: [F]ive directors is almost always a minimum

for an effective and

properly functioning board. (2015 Puma

Biotechnology Proxy Paper)

Council of Institutional Investors

Corporate Governance Policies: [A]

board should have no fewer than five

and no more than 15 members.

Puma's current board would have you believe that a five member board is appropriate for effectively governing the Company and that the board's current size provides for efficient decision-making.

Puma's claims contradict best practices and industry norms:

Best Practices

Industry Norms

Numerous companies, including Fortune 500 companies, have boards with nine directors: United Natural Foods Inc., Windstream Holdings, Inc., Dr. Pepper Snapple Group, Inc., Lennar Corporation, Laboratory Corp of America Holdings, Inc., Graybar Electric Company Inc. Wynn Resorts, Limited, St. Jude Medical, Inc., Asbury Automotive Group, Big Lots, Inc., Enterprises Inc., Quintiles Transnational Holdings Inc., Joy Global Inc., Lorillard, Inc., Sanmina, First American Financial Corp., Allergan Inc., Omnicare Inc., Dick's Sporting Goods, NCR Corporation, Waste Management, Inc., PPG Industries Inc., Marathon Stores, Inc., Agilent Technologies Inc., Symantec Corporation, HollyFrontier Corporation, PBF Energy Inc., Kohl's Corporation, Incorporated, Clovis Oncology, Inc., Tesoro Corporation, ARIAD Pharmaceuticals, Inc., Dynavax Technologies Corporation, Seattle Genetics, Inc., Tesaro, Inc., World Fuel Services Corporation, INTL FCStone Inc., Best Buy Co. Inc, Reliance Steel & Cognizant Technology Solutions, Ball Corporation, Broadcom Corporation, CenterPoint Energy, Franklin Resources, Inc., Ocal Corporation, Mohawk Industries, Inc., UGI Corporation, The Pantry, Inc., Tyson Foods Inc., Jabil Circuit, Inc., AutoNation Inc., Processing Inc., Liberty Interactive Corporation, Ameriprise Financial, Inc., Centene Corporation, Huntsman Corporation, DeVere Markets, Inc., Tech Data Corporation, RiteAid Corporation, National Oilwell Varco, Inc., Xerox Corporation, Arroyo Belden Inc., Eastgroup Properties Inc., La-Z-Boy Inc., Amphenol Corporation, CVR Energy Corp, International Bancshares C

#### Current Board's Lack Of Experience

Puma claims that the current board members possess a well diversified range of experience and the current board has the experience necessary to guide the Company through the next stages of its development.

The current board has limited public company corporate governance and oversight experience:

o

The current board has collectively only served on 6 public boards other than Puma.

Of these companies, the five that remain public have a current combined market cap of \$3.21 billion,

1

only slightly larger than Puma itself, of which Radius Health, Inc. accounts for \$2.63 billion. Their average market cap was only \$642.9M.

Mr. Wilson serves on the board of Zosano, Inc. which since becoming public in 2015 is down approximately 75%.

The stock price of Radius Health, Inc., where Mr. Auerbach is a director, fell 11% after the company delayed an NDA filing for work health balance, and was down 23% from its peak in July 2015.

The Nominees are far more experienced than the current board:

The four Nominees have served on at least 20 public company boards

more than 3x

the five

current board members.

The four Nominees have served as Chairman or Lead Director on at least 10 public and private company boards

10x

the five current board members.

The four Nominees have at least 110 years of combined relevant industry experience in the pharmaceutical and biotechnology industry as officers and directors

nearly double

the five

current board members purported 60 years of experience.

43

1. All calculations as of November 24, 2015.

Nominee Experience

44

Puma claims that the Nominees provide no additional experience or expertise.

In fact, the Nominees will add extensive expertise that the current board lacks:

Drug Development and Regulatory

Current

Board

Nominees

Auerbach's experience at Cougar was limited to an in-licensed drug - early development was completed by PFE; Cougar was sold before any NDA filing.

Three Nominees have extensive development experience:

Dr. Seth A. Rudnick was responsible for the development and approval of two significant biologicals - alpha interferon and erythropoietin, at Schering Plough/Biogen and Johnson & Johnson, respectively.

Dr. Eshelman has supervised drug development and approvals in many therapeutic areas.

Mr.

James M. Daly worked closely on clinical development, regulatory, and oncology pipeline strategy at both Amgen Inc. and Incyte Corporation.

M&A

Current

Board

Nominees

No one on the current board has M&A experience other than Auerbach, who was involved in the sale of Cougar for \$1.1B.

Three Nominees have played key roles in large strategic transactions:

Dr.

Eshelman's

previous companies combined

have

sold

for

approximately

\$5

billion-

more

than

5x

the

value of Auerbach's previous transaction that Puma touted in its Revocation Statement.

Mr. Kenneth B. Lee, Jr. served as a director for three companies that were sold in transactions with a combined value of approximately \$7.8B, and served on the Transaction Committee and Audit Committee of Pozen Inc. during its acquisition of Tribute Pharmaceuticals Canada Inc.

o

Lee also founded the Center for Strategic Transactions at Ernst & Young LLP.

Mr. Daly played a key role in Amgen's acquisitions of Micromet and BioVex, both oncology products.

Oncology

Current

Board

Nominees

The

current board

members have

limited

oncology background.

All Nominees have significant oncology experience:

Dr. Rudnick is a medical oncologist and completed an oncology fellowship at Yale University.

Daly served as head of Amgen's oncology business. He oversaw the successful launches of five oncology products and played a key role in two oncology product acquisitions.

Dr.

Eshelman has served on the boards of numerous

companies that developed oncology products.

Mr. Lee served on the board of an oncology company, OSI Pharmaceuticals, Inc., that had a

marketed

product

and

was

acquired

by

Astellas

Pharma,

Inc.

Nominee Experience

45

Investment

Current Board

Nominees

Only one current board  
member has significant

investment experience.

Three

Nominees have significant investment experience focused on breakthrough and early stage companies, at funds with a venture capital model.

Dr. Eshelman: Founder of Eshelman Ventures LLC., a fund managing investments in numerous healthcare companies.

Dr. Rudnick: 15 years of investment experience.

Venture Partner at Canaan Partners, led

investments in several breakthrough companies, including CombinatoRX, Esperion, Genaisance Pharmaceuticals and Pozen.

Mr. Lee: General Partner of Hatteras BioCapital Fund., L.P., where he managed portfolios valued at over

\$200M.

Accounting

Current

Board

Nominees

No current board

members have

accounting experience

except for Jay M.

Moyes, who spent 12

years at KPMG LLP.

Mr. Lee spent 28 years at Ernst & Young LLP.

Titles included: Managing Director of Health Sciences Investment Banking Group & Co-Chairman of International Life Sciences Practice.

Strong understanding of GAP and GAAP as applied to life sciences.

Unique experience structuring transactions at ALZA Corporation.

Marketing

Current

Board

Nominees

No current board

members have

significant marketing

experience.

Mr. Daly was responsible for marketing in his role as Chief Commercial Officer at Incyte and during his time at Amgen, where he served as SVP North America Commercial Operations and SVP Global Marketing and Commercial Development.

During Daly's tenure at Incyte, annual

oncology

sales increased from \$130M to \$600M per year,

and during his tenure

as head of the oncology business at Amgen sales increased from \$1B to \$4B.

#### CAREER HIGHLIGHTS

Age: 66

Founder of Eshelman Ventures, LLC, an investment company primarily focused on healthcare companies.

Non-Executive Chairman of The Medicines Company, a global biopharmaceutical company focused on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on the leading acute and intensive care

hospitals worldwide

Founded and served as CEO and Executive Chairman of Pharmaceutical Product Development, Inc.,

a global contract pharmaceutical research organization. In 2008,

PPD was selected by Forbes for its Platinum 400 list of the best big companies in America and as best-managed company in health care equipment and services.

PPD was sold to a private equity consortium for \$3.9 billion in December 2011.

Served as Founding Chairman and largest shareholder of Furiex Pharmaceuticals, Inc., which licensed and rapidly developed new medicines.

Furiex was separated

from PPD in a tax-free spin-off in June 2010 and sold to Forest Labs/Actavis for \$1.1 billion in July 2014.

Served as Senior Vice President, Development of Glaxo, Inc., predecessor to GlaxoSmithKline plc, as well as in various management positions with Beecham Laboratories and Boehringer Mannheim Pharmaceuticals.

Served on the executive committee of the Medical Foundation of North Carolina and the Board of Trustees for UNC-Wilmington. In 2011, Dr. Eshelman was appointed by the North Carolina General Assembly to serve on the Board of Governors for the state's multi-campus university system as well as the North Carolina Biotechnology Center. In addition, he chairs the board of visitors for the School of Pharmacy at UNC-Chapel Hill, which was named the UNC Eshelman School of Pharmacy in recognition of his many contributions to the school and the profession.

Awards received by Dr. Eshelman include the Davie and Distinguished Service Awards from UNC and Outstanding Alumnus from both the UNC and University of Cincinnati schools of pharmacy, as well as the North Carolina Entrepreneur Hall of Fame Award.

FREDRIC N. ESHELMAN, PHARM.D.

46

NOMINEE

EDUCATION

Received

Pharm.D.

from

the

University

of

Cincinnati,

and

completed

a

residency

at

Cincinnati

General

Hospital

and

a

B.S.

in

pharmacy

from  
UNC-  
Chapel  
Hill.  
Dr.  
Eshelman  
is  
a  
graduate  
of  
the  
Owner/President  
Management  
program  
at  
Harvard  
Business  
School.

CAREER HIGHLIGHTS

Age:

53

Mr.

Daly  
served

as

Executive  
Vice  
President  
and  
Chief  
Commercial  
Officer  
at  
Incyte  
Corporation,  
a  
biopharmaceutical  
company,  
from  
October  
2012  
until  
June  
2015.  
Mr.  
Daly  
has  
served  
as  
one  
of  
Chimerix  
Inc s  
directors  
since  
2014.  
Prior  
to  
joining  
Incyte,  
Mr.  
Daly  
served  
as  
Senior  
Vice  
President  
of  
North  
America  
Commercial  
Operations  
and  
Global  
Marketing/Commercial

Development  
at  
Amgen  
Inc.,  
a  
global  
pharmaceutical  
company,  
where  
he  
was  
employed  
from  
January  
2002  
to  
December  
2011.  
Prior  
to  
his  
employment  
with  
Amgen,  
Mr.  
Daly  
was  
Senior  
Vice  
President  
and  
General  
Manager  
of  
the  
Respiratory/Anti-infective  
business  
unit  
at  
GlaxoSmithKline,  
where  
he  
was  
employed  
from  
June  
1985  
to  
December  
2001.

JAMES M. DALY

47

NOMINEE

EDUCATION

Received

a

B.S.

and

an

M.B.A.

degree

from

the

University

of

Buffalo,

The

State

University

of

New

York.

#### CAREER HIGHLIGHTS

Age: 66

Dr. Seth Rudnick has been venture partner and previously general partner at Canaan Partners, a venture capital firm, since 1998, from which he is now retired.

Formerly, Dr. Rudnick was the Chief Executive Officer and Chairman of CytoTherapeutics Inc., a company developing stem cell-based

therapies. He helped found and served as the Head of Research and Development for Ortho Biotech, a division of Johnson & Johnson focusing on cancer and chronic illnesses.

Dr. Rudnick currently serves on the boards of directors of the following privately held biotechnology companies: Envisia Therapeutics, LQ3 Therapeutics, Meryx Pharmaceuticals, for which he serves as Chairman, Liquidia Technologies, Inc., for which he serves as Chairman, and G1 Therapeutics, for which he serves as Executive Chairman.

Dr. Rudnick also served on the board of Square 1, a public company until its October 2015 acquisition by Pacific Western Bank. Currently Dr. Rudnick

is a Clinical Adjunct Professor of Medicine at University of North Carolina, Chapel Hill.

SETH A. RUDNICK, M.D.

48

NOMINEE

EDUCATION

Received

M.D.

from

the

University

of

Virginia.

Completed

a

residency

at

Washington

University

Barnes

Hospital

and

a

fellowship

in

medical

oncology

at

Yale

University.

Holds

a

B.A.

in

history

from

the

University

of

Pennsylvania.

**CAREER HIGHLIGHTS**

Age: 67

Managing member of Hatteras BioCapital, LLC  
and the general

partner of Hatteras BioCapital Fund, L.P., a venture capital fund  
focusing on life sciences companies.

Mr. Lee most recently served as managing director of the firm s

Health Sciences Corporate Finance Group.

Currently, Mr. Lee serves on the boards of directors of the following publicly held biotechnology companies: Biocryst Pharmaceuticals, Inc.

and

Pozen Inc., for which he serves as Lead Director, Chairman of the compensation committee and as a member of the audit committee.

Mr. Lee also serves on the boards of directors of two private companies,

Clinverse, Inc., and Clinipace Worldwide Inc., for which he serves as Chairman, and is a co-founder of the National Conference on Biotechnology Venture.

Between 2002 and 2013, Mr. Lee served on the Boards of several public companies: Maxygen, Inc.; OSI Pharmaceuticals, Inc.; CV Therapeutics, Inc.; Abgenix, Inc. and Inspire Pharmaceuticals, Inc.

Mr. Lee was formerly national director of the life science practice at Ernst and Young LLP, where he advised biotechnology and pharmaceutical companies throughout the world on a wide range of financial and strategic planning issues.

KENNETH B. LEE, JR.

49

NOMINEE

EDUCATION

Received

a

B.A.

in

from

Lenoir-Rhyne

College

and

an

M.B.A.

from

the

University

of

North

Carolina

at

Chapel

Hill.

Contact

50

Legal Inquiries:

Cadwalader, Wickersham & Taft LLP

Richard Brand

(212) 504-5757

[richard.brand@cwt.com](mailto:richard.brand@cwt.com)

Investor Inquiries:

Okapi Partners LLC

Bruce Goldfarb/ Pat McHugh/ Lydia Mulyk

(212) 297-0720 or (877) 869-0171

info@okapipartners.com

Media Inquiries:

Finsbury

Kal

Goldberg/ Chuck Nathan / Chris Ryall

(646) 805-2000

kal.goldberg@finsbury.com

charles.nathan@finsbury.com

chris.ryall@finsbury.com

Appendix A  
Executive Compensation  
51

History of Problematic Statements:

Soaring Stock Price & Effect On Executive Compensation

While the stock price was high between July 2014 and June 2015, Chairman, President and CEO Alan Auerbach and SVP Finance and Administration and Treasurer Charles Eyler were each rewarded with generous cash and stock bonuses for 2014.

52

In its Proxy statement, filed in April 2015, the Company justified its 2014 executive

compensation program on the following factors:

Price of the common stock increased approximately 1,302% between the Company's initial OTC listing in April 2012 and the end of its 2014 fiscal year.

Price of the common stock increased approximately 83% during the Company's 2014 fiscal year.

Positive ExteNET results announced by the Company in July 2014.  
Eylar:

\$117,610 cash bonus

Options to purchase 31,500 shares

Total Value: \$4,499,559

Auerbach:

\$300,000 cash bonus

Options to purchase 150,000 shares

Total Value: \$17,797,606

Sources: SEC Filings.

Stockholder Unfriendly

Executive Compensation

The Company's overall executive compensation program is excessive, is not aligned with shareholder interests, and does not reflect best practices.

Puma's executive and director compensation levels are excessive.

Alan Auerbach's total annual compensation for 2014 was almost 8x the ISS peer group median and included an outsized equity award equal to more than 26x his base salary.

Puma's outside directors each received compensation in excess of \$1.175 million for 2014.

Failure to implement formula-based incentive plans with objective metrics and goals.

Puma has a discretionary executive cash bonus program and does not use any performance-vesting equity awards for its executives.

Both ISS and Glass Lewis have identified Puma's executive compensation program as not being linked to performance and concerns with the structure of long-term incentive pay.

53

Stockholder Unfriendly

Executive Compensation

Executive compensation practices that are not consistent with best practices and investor expectations.

Puma only provides its stockholders with an opportunity to vote on its executive compensation program once every three years (triennial say-on-pay). In 2014, only 15.4%

of Russell 3000 companies provided triennial votes.

Puma discloses no clawback, anti-hedging or anti-pledging policies.

CEO Auerbach has 280G gross-up protection.

Puma's equity incentive plan is dilutive and expensive.

More than 1/3 of Puma's stockholders voted against the 2015 and 2014 equity plan proposals to approve additional shares to increase plan capacity.

According to Glass Lewis, the total potential dilution from the plan is 31.97%, while peer average total dilution is 20.41% and the peer median is 18.67%, and the three-year burn rate is more than 2x the peer median rate (5.64% v. 2.80%). ISS calculated the one-year 2014 burn rate at 6.62%.

Glass Lewis calculated the projected annual cost of the plan per employee at more than 22x the peer average, with an annual per employee cost of over \$2.5 million.

1. Source: Towers Watson.

54

Puma's compensation practices reflect a board that is not responsive to shareholder concerns.

1